Activation of the kynurenine pathway is associated with poor outcome in Pneumocystis pneumonia patients infected with HIV: results of 2 months cohort study

[1]  Dajin Li,et al.  The role of indoleamine‐2,3‐dioxygenase in normal and pathological pregnancies , 2018, American journal of reproductive immunology.

[2]  Nycolas W Preite,et al.  The IDO–AhR Axis Controls Th17/Treg Immunity in a Pulmonary Model of Fungal Infection , 2017, Front. Immunol..

[3]  Jianpei Fang,et al.  Indoleamine 2,3-dioxygenase and inducible nitric oxide synthase mediate immune tolerance induced by CTLA4Ig and anti-CD154 hematopoietic stem cell transplantation in a sensitized mouse model , 2017, Experimental and therapeutic medicine.

[4]  R. Chaisson,et al.  Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Richard D Moore,et al.  Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. , 2016, The Journal of infectious diseases.

[6]  M. Yin,et al.  Plasma IL-6/IL-10 Ratio and IL-8, LDH, and HBDH Level Predict the Severity and the Risk of Death in AIDS Patients with Pneumocystis Pneumonia , 2016, Journal of immunology research.

[7]  Q. Wang,et al.  Indoleamine 2,3-Dioxygenase Is Involved in the Inflammation Response of Corneal Epithelial Cells to Aspergillus fumigatus Infections , 2015, PloS one.

[8]  Jeffrey N. Martin,et al.  The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. , 2014, The Journal of infectious diseases.

[9]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[10]  Hongzhou Lu,et al.  Anti-Retroviral Therapy Decreases but Does Not Normalize Indoleamine 2,3-Dioxygenase Activity in HIV-Infected Patients , 2014, PloS one.

[11]  S. Schmidt,et al.  New Insights into IDO Biology in Bacterial and Viral Infections , 2014, Front. Immunol..

[12]  G. Prendergast,et al.  Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. , 2012, The Journal of infectious diseases.

[13]  K. Chida,et al.  Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. , 2011, The Journal of infection.

[14]  D. Boulware,et al.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.

[15]  A. Copas,et al.  Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia , 2010, International journal of STD & AIDS.

[16]  Pierre Tattevin,et al.  Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. , 2010, The Journal of infectious diseases.

[17]  J. Laine,et al.  HIGH ACTIVITY OF INDOLEAMINE 2,3 DIOXYGENASE ENZYME PREDICTS DISEASE SEVERITY AND CASE FATALITY IN BACTEREMIC PATIENTS , 2010, Shock.

[18]  M. Baccarani,et al.  Tolerance: Focus on Hematology the Role of Indoleamine 2,3-dioxygenase in the Induction of Immune , 2008 .

[19]  L. Jarlsberg,et al.  Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: An observational cohort study , 2009, Scandinavian journal of infectious diseases.

[20]  A. De Luca,et al.  Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus. , 2009, Medical mycology.

[21]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[22]  T. Lehtimäki,et al.  Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality , 2006, Mechanisms of Ageing and Development.

[23]  D. Fuchs,et al.  Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. , 2002, Clinical immunology.

[24]  M. Gompels,et al.  Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.